Modern cancer treatment for insured persons of the United Guild health insurance before the end? Bad times for good medicine for patients? Becomes apparent that an exclusively income-oriented and at the Spardikat of health insurance health care meet the needs of patients not just in cancer medicine can meet. The case of patients is increasingly ignored and it is threatening a two-class health care, as well as the absence of innovative methods. The consequences of “health reform policy” under Ulla Schmidt are becoming increasingly evident. Current patients are insured of the United Guild health insurance, who suffer prostate cancer with subsequent urinary incontinence (loss of the aptitude to keep the urine), and which innovative medicines should no longer be paid from this Fund. Improved early diagnosis and new treatment approaches can be the most common tumor of the man, the prostate cancer, in many cases cured or achieved at least a growth arrest. A small percentage of Prostate cancer patients suffers from a urinary incontinence (bladder weakness), which can be significantly improved with the new active ingredient ‘Duloxetine’ (Yentreve) or completely healed.
Officially, this drug is approved in Germany for women. Numerous studies on the effectiveness of Yentreve in the treatment of bladder weakness have been in men. This therapeutic alternative to no longer are now insured of the United Guild health insurance available. Introduction of testing methods of the physicians Association of Westfalen-Lippe, United Guild health insurance reclaim the treatment cost of treating urologists for the year 2006 under the indication that it is a regulation within the meaning of off-label use, which is not allowed for insured persons of the United Guild health insurance. Off-Labeluse refers to the regulation of approved medicinal outside of the authorisation requested and approved use, national or European regulatory authorities for example, with regard to the applications, the dose or treatment duration. On German speaking of admission ueberschreitendem usage or approval-process application of medicines.
In many medical areas, especially the Pediatrics and Oncology, a large part of the drugs for the benefit of the patient applied off label, to maintain the modern medical standards. The eligibility of off-label was the subject of legal disputes before the Bundessozialgericht repeatedly use prescribed medicines by the statutory health insurance. What is the Outlook got patients after health-care reform in the face of individual contracts, hospital privatization, medical centres, Zuzahlungem Diseasemangamentprogrammen and medicinal subrogation against doctors, she prescribed an effective innovative treatment can get? Increasingly fewer resources available to the supply are cause by the under-funding of curative medicine and not associated with the health services financing To ensure patients by modern medical standards. Just established doctors have a tangible issue by the impending regresses in the off-label use. You bear the full financial responsibility for the funds if they don’t pay the medicines and are on the other side to their Patientenverpflichtet, to represent an optimal therapy. So there is a conflict between the practice’s own economic situation or their ruin and the optimal care of patients on the other hand.Patients can sue if they don’t get medications due to failure to assist. It is urgent to demand a clear regulation for such cases, leaving the United Guild insurance duty, here to participate, so that patients keep the faith in our health care.
